Johnson & Johnson And Legend Biotech Corp Announce CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's CARVYKTI, a cell therapy, has shown a 45% reduction in the risk of death for multiple myeloma patients in the CARTITUDE-4 study, making it the first therapy to significantly extend overall survival compared to standard treatments.
September 27, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's CARVYKTI has demonstrated a significant 45% reduction in the risk of death for multiple myeloma patients, outperforming standard therapies. This positions CARVYKTI as a leading cell therapy in the market.
The significant reduction in death risk and the positioning of CARVYKTI as the first cell therapy to improve overall survival in multiple myeloma patients is a major advancement. This could lead to increased adoption and sales, positively impacting JNJ's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100